Zoetis Inc - Class A ZTS Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$79.40 down $2.71, 3.30% at close Nov 6
Last close · Previous close $82.11
- Market cap
- At the Nov 6 close
- P/E ratio
- 13.08On last 12 months’ EPS
- Diluted EPS
- $6.07Last 12 months
- Dividend yield
- 2.67%Last 12 months
Price chart
$79.40down $2.71, 3.30%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$82.11Nov 5
- Volume5.80MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume4.39MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $68.77 to $132.49; now $79.40
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ZTS beat the S&P 500 in 2 of 7 periods.
| Period | ZTS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ZTS: up 12.1% S&P 500: down 5.6% | ZTS beat the S&P 500 by 17.7 percentage points Beat |
| 3M | ZTS: up 3.4% S&P 500: down 4.1% | ZTS beat the S&P 500 by 7.5 percentage points Beat |
| YTD | ZTS: down 35.5% S&P 500: up 8.7% | ZTS trailed the S&P 500 by 44.2 percentage points Trailed |
| 1Y | ZTS: down 32.1% S&P 500: up 10.9% | ZTS trailed the S&P 500 by 43.0 percentage points Trailed |
| Long term | ||
| 3Y | ZTS: down 49.1% S&P 500: up 75.0% −20.1% vs +20.5% a year | ZTS trailed the S&P 500 by 124.1 percentage points Trailed |
| 5Y | ZTS: down 61.0% S&P 500: up 67.8% −17.2% vs +10.9% a year | ZTS trailed the S&P 500 by 128.8 percentage points Trailed |
| 10Y | ZTS: up 74.4% S&P 500: up 313.1% +5.7% vs +15.2% a year | ZTS trailed the S&P 500 by 238.7 percentage points Trailed |
$10,000 invested in ZTS 10 years ago (Nov 4, 2016) would be worth about $17,435 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ZTS beat the S&P 500 in 2 of 7 periods.
| Period | ZTS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ZTS: up 11.3% S&P 500: down 5.6% | ZTS beat the S&P 500 by 16.9 percentage points Beat |
| 3M | ZTS: up 2.8% S&P 500: down 4.3% | ZTS beat the S&P 500 by 7.1 percentage points Beat |
| YTD | ZTS: down 36.9% S&P 500: up 7.8% | ZTS trailed the S&P 500 by 44.7 percentage points Trailed |
| 1Y | ZTS: down 33.6% S&P 500: up 9.7% | ZTS trailed the S&P 500 by 43.3 percentage points Trailed |
| Long term | ||
| 3Y | ZTS: down 51.3% S&P 500: up 68.8% −21.3% vs +19.1% a year | ZTS trailed the S&P 500 by 120.1 percentage points Trailed |
| 5Y | ZTS: down 63.4% S&P 500: up 56.9% −18.2% vs +9.4% a year | ZTS trailed the S&P 500 by 120.3 percentage points Trailed |
| 10Y | ZTS: up 59.0% S&P 500: up 252.6% +4.7% vs +13.4% a year | ZTS trailed the S&P 500 by 193.6 percentage points Trailed |
$10,000 invested in ZTS 10 years ago (Nov 4, 2016) would be worth about $15,899 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$247.03
Closing high on . Now 67.9% below that record.
Split-adjusted daily closes since Feb 1, 2013.
Stock splits
ZTS hasn’t split since its price history begins in 2013.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $9.52Bup 1.5%
- Net income
- $2.62Bup 1.0%
- Diluted EPS
- $6.07up 5.4%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $2.39B | $682.00M | $1.50 |
| Q4 FY24 (Dec 31, 2024) | $2.32B | $581.00M | $1.29 |
| Q1 FY25 (Mar 31, 2025) | $2.20B | $602.00M | $1.34 |
| Q2 FY25 (Jun 30, 2025) | $2.47B | $726.00M | $1.63 |
| Q3 FY25 (Sep 30, 2025) | $2.40B | $721.00M | $1.63 |
| Q4 FY25 (Dec 31, 2025) | $2.39B | $603.00M | $1.37 |
| Q1 FY26 (Mar 31, 2026) | $2.26B | $601.00M | $1.42 |
| Q2 FY26 (Jun 30, 2026) | $2.47B | $691.00M | $1.65 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $7.78B | $2.04B | $4.27 |
| FY22 (Dec 31, 2022) | $8.08B | $2.11B | $4.49 |
| FY23 (Dec 31, 2023) | $8.54B | $2.34B | $5.07 |
| FY24 (Dec 31, 2024) | $9.26B | $2.49B | $5.47 |
| FY25 (Dec 31, 2025) | $9.47B | $2.67B | $6.02 |
Margins
- Gross 71.5%
- Operating 36.9%
- Net 27.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $2.38BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$2.89BLast 12 months
- Capital spending$510.00MLast 12 months
- 25.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $3.64BLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$889.00MLast 12 months
- Total returned$4.53BLast 12 months
191% of free cash flow
Balance sheet
- $1.68BAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$9.24BAs of Jun 30, 2026
- Net debt$7.56BAs of Jun 30, 2026
- 3.08As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 2.93As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 68.9%Last 12 months
Over the last 12 months, Zoetis’s net income was 68.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 17.2%Last 12 months
Over the last 12 months, Zoetis’s net income was 17.2% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.38 |
| 2017 | $0.42 |
| 2018 | $0.50 |
| 2019 | $0.66 |
| 2020 | $0.80 |
| 2021 | $1.00 |
| 2022 | $1.30 |
| 2023 | $1.50 |
| 2024 | $1.73 |
| 2025 | $2.00 |
| 2026 (to date) | $2.12 |
Dividend details
- $2.12Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- Dividend yield2.67%Last 12 months
- $0.53Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencyQuarterly4 payments in the last 12 months
- up 20.1% a yearFull years 2020–2025
The compound annual growth rate of the full-year dividend per share from 2020 to 2025.
- 11 yearsThrough 2025
How many calendar years in a row the full-year amount has risen, through 2025.
- 34.9%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About Zoetis Inc - Class A
The action alleges Zoetis and certain officers made materially false and misleading statements regarding the Company's Companion Animal product portfolio, concealing safety concerns with Librela, competitive losses in parasiticides and dermatology, and declining veterinarian confidence. Four corrective disclosures between August 2025 and May 2026 allegedly removed artificial inflation from ZTS shares. "The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests in the outcome of the litigation. Investors with losses in Zoetis during the Class Period should evaluate whether seeking appointment serves their interests before the July 27 deadline." -- Joseph E. Levi, Esq. Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com Frequently Asked Questions About the ZTS Lawsuit Q: What is the ZTS lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is July 27, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date. Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run. Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery. Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs. Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices. Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 SOURCE Levi & Korsinsky, LLP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
ZTS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ZTS stock FAQ
What is ZTS stock’s price today?
Zoetis (ZTS) traded at $79.40 at the close on , down $2.71 (3.30%) from the previous close of $82.11. Over the past 52 weeks it has traded between $68.77 and $132.49.
If you invested $1,000 in ZTS 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ZTS on would be worth about $1,744 at the close on , a total return of +74.4%. The same $1,000 would be worth $390 if invested five years ago and $679 if invested one year ago. Past performance doesn’t predict future returns.
What is ZTS’s P/E ratio?
ZTS trades at 13.1 times its diluted earnings over the four quarters to ($6.07 per share), at the close. (How the P/E ratio works.)
How much revenue does Zoetis make?
Zoetis reported $9.5 billion of revenue over the four quarters to , up 1.5% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $2.5 billion, down 0.2% from a year earlier.
Is Zoetis profitable?
Yes. Zoetis earned $2.6 billion of net income over the four quarters to , a net margin of 27.5%, and its operating margin was 36.9% (what margins tell you).
What are ZTS’s earnings per share?
ZTS’s diluted earnings per share were $6.07 over the four quarters to , compared with $5.76 in the twelve months before. The latest quarter (Q2 FY26) brought $1.65 per share, against $1.63 a year earlier (how EPS works).
Does ZTS pay a dividend?
Yes. Zoetis pays a quarterly dividend. The most recent was $0.53 per share, with an ex-dividend date of . Over the last twelve months it paid $2.12 per share, a 2.67% yield at the close, and the full-year dividend has risen 11 years in a row (how dividend yield works).
Based on the last 12 months’ payments ($2.12 per share), and if the next 12 months match the last 12, 100 shares would receive about $212 over 12 months, and $1,000 over 12 months would take about 472 shares, roughly $37,477 at the close. Dividends can change.
What is ZTS’s 52-week high and low?
Over the past 52 weeks ZTS has traded as low as $68.77 and as high as $132.49. At $79.40 at the close on , it is 40.1% below that high and 15.5% above the low.
What is ZTS’s all-time high?
ZTS’s highest closing price was $247.03 on , adjusted for stock splits. At $79.40 at the close on , it is 67.9% below that record.
Has ZTS stock ever split?
No. ZTS hasn’t split since its price history begins in 2013.
How has ZTS stock performed?
Including dividends and measured to the close on , ZTS has returned −35.5% so far this year and −32.1% over the past year, and −61.0% over five years (−17.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Zoetis in?
Zoetis is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in New Jersey, USA.
What exchange does ZTS trade on?
Zoetis trades on the NYSE under the ticker symbol ZTS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.